Novo Nordisk: Wegovy Pill Reaches 2 Million Prescriptions while Competitor Eli Lilly Records a Tepid Start with Foundayo!

The stock of Novo Nordisk is gaining momentum again after a two-day bullish consolidation. At the same time, the multi-week bottom formation has been completed. For traders who operate with tight risk tolerance, the stock is providing a short-term green light. Where does this new strength come from? 1. The most important catalyst is the high demand for the newly introduced Wegovy pill. Since its launch on January 5, 2026, there have already been 2 million prescriptions. It is performing better than expected. "As the global momentum for peptide-based...